New therapeutic approach for treatment age-related macular degeneration (AMD)

Exudative age-related macular degeneration is leading cause of irreversible vision loss in developed countries. Subfoveal localization of choroidal neovascular membrane is the most difficult form for treatment. At the last three years, the new group of agens well-known as anti-VEGF agens was approved for treatment of exudative AMD. In that purpose, intravitreally administrated agens is recommended. Efficacy and safety of anti-VEGF agens were proved in short-time follow up period.